Physician profile
Lisa K Mathew
NPI 1639331200
$10,481.16
in general payments reported to CMS, 2019-2025
35 companies · $3,356 in 2025
The $3,356 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $49.04 · 2021: $586 · 2022: $1,367 · 2023: $1,839 · 2024: $3,017 · 2025: $3,356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,173 · Education: $38.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,173.00 |
| Education | $38.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,213.77 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,489.73 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,204.32 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $834.69 | 2021-2025 | Tremfya, Stelara, Remicade |
| Celgene Corporation | $523.70 | 2021-2024 | Zeposia |
| Genzyme Corporation | $516.60 | 2022-2025 | |
| Pfizer INC. | $414.66 | 2019-2025 | |
| Lilly USA, LLC | $411.37 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $406.54 | 2022-2025 | Ibsrela |
| Gilead Sciences, INC. | $362.09 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $347.87 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $226.05 | 2021-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $185.34 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $173.57 | 2019-2025 | Rebyota |
| Phathom Pharmaceuticals, INC. | $162.82 | 2024-2025 | Voquezna |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $142.04 | 2021-2025 | Renflexis, Hadlima |
| Novo Nordisk INC | $137.85 | 2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $116.63 | 2019-2025 | Ocaliva |
| Redhill Biopharma INC. | $112.52 | 2021-2023 | Talicia, Movantik, Aemcolo |
| Ipsen Biopharmaceuticals, INC | $77.94 | 2024-2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $72.66 | 2023-2024 | Dificid, Zinplava |
| Nestle Healthcare Nutrition INC. | $44.06 | 2022-2023 | |
| Ucb, INC. | $36.96 | 2019 | |
| Ironwood Pharmaceuticals, INC | $34.41 | 2024 | |
| Allergan, INC. | $28.34 | 2019-2020 | |
| Celltrion USA INC. | $28.07 | 2023 | Yuflyma |
| Medtronic, INC. | $27.36 | 2024 | Interstim |
| Aimmune Therapeutics, INC. | $26.58 | 2025 | Zenpep |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.00 | 2023 | |
| Amgen INC. | $21.59 | 2025 | Uplizna |
| Braintree Laboratories, INC. | $19.94 | 2021 | |
| Alnylam Pharmaceuticals INC. | $18.01 | 2021 | |
| Ethicon US, LLC | $15.08 | 2020 | |
| Erbe USA INC | $12.52 | 2019 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.